Infectious complications in 100 consecutive heart transplant recipients
Détails
ID Serval
serval:BIB_8AEF67215768
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Infectious complications in 100 consecutive heart transplant recipients
Périodique
European Journal of Clinical Microbiology and Infectious Diseases
ISSN
0934-9723
Statut éditorial
Publié
Date de publication
01/1994
Peer-reviewed
Oui
Volume
13
Numéro
1
Pages
12-8
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jan
Research Support, Non-U.S. Gov't --- Old month value: Jan
Résumé
Clinical and laboratory data on infectious complications in 100 consecutive heart transplant recipients were analyzed retrospectively. The mean length of follow-up was 651 +/- 466 days. All patients received a basic immunosuppressive regimen including cyclosporine (whole blood target trough level 400-600 micrograms/l), azathioprine (1 mg/kg/day) and prednisone (0.15 mg/kg/day). Early rejection prophylaxis consisted of polyclonal rabbit antithymocyte globulin (ATG) (4 mg/kg/day for 4 days) in the first 57 patients and monoclonal murine OKT-3 (5 mg/day for 14 days) in the remaining patients. The primary cause of death was infection in three patients and rejection in 16 (p < 0.001). The incidence of infection was 0.96/patient/year (n = 179); 95 infections were nosocomial (53%), 47 community-acquired (26%) and 37 opportunistic (21%). The number of hospitalizations due to infections was fewer than that due to rejection (53 versus 246 respectively, p < 0.0001), but the mean length of hospital stay was longer in the first group (13.85 +/- 10.92 days versus 3.48 +/- 2.28 days, p < 0.001). Previous early rejection prophylaxis with OKT-3 was associated with a greater number of opportunistic and nosocomial infections compared to prophylaxis with ATG (p < 0.05), as was treatment with ATG and steroid pulses compared to steroid pulses alone in cases of opportunistic infection (p < 0.05).
Mots-clé
Adult
Antilymphocyte Serum/therapeutic use
Community-Acquired Infections/*epidemiology/etiology
Cross Infection/*epidemiology/etiology
Female
Follow-Up Studies
Graft Rejection/prevention & control
*Heart Transplantation
Humans
Immunocompromised Host
Immunosuppressive Agents/administration & dosage
Male
Middle Aged
Muromonab-CD3/therapeutic use
Opportunistic Infections/*epidemiology/etiology
Postoperative Complications/*epidemiology
Retrospective Studies
Pubmed
Web of science
Création de la notice
14/02/2008 14:16
Dernière modification de la notice
20/08/2019 14:49